Hydroxychloroquine (Plaquenil)
StandardMost people with lupus · tablet
One of the main lupus medicines. The Lupus Foundation of America notes it also helps protect against sun sensitivity. It needs regular eye checks.
There is no cure for lupus (systemic lupus erythematosus, or SLE), but it can be treated. In lupus the immune system attacks the body's own tissues, including skin, joints and kidneys. Hydroxychloroquine, steroids and immune-calming drugs are the base of care, and four targeted drugs are now FDA approved for lupus or its kidney form. One of them, Gazyva (obinutuzumab), is approved for lupus kidney disease, and the FDA is expected to decide by December 2026 whether to approve it for lupus more broadly. Our view: the biggest news is from cell therapies that wipe out and "reset" B cells. Small studies report remissions that last after other drugs are stopped. They are still experimental, with follow-up measured in months to a few years.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a lupus-experienced medical team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your rheumatologist.
After a deep B-cell reset, could a blood test that watches whether the old disease-linked B-cell and plasma-cell families come back warn of relapse months before symptoms? If so, those people might one day get a narrow second step aimed only at those cells, a treatment that does not yet exist for people. In lupus mice, removing just the plasma cells that make anti-DNA antibodies eased kidney disease (PNAS, 2026).
What would prove it wrong: if relapses after a reset come from brand-new B-cell families rather than old ones, or if the return of old families does not come before relapse.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In a 20-year, single-hospital look back at 702 people with lupus nephritis (lupus kidney disease), 149 got a BLyS-blocking drug (belimumab or telitacicept) on top of standard care. More of them were able to stop steroids (10.7% vs 5.6%, P = 0.026). No kidney flares were seen in those who stopped on a BLyS blocker, though the difference from the other group was not statistically clear. It is a retrospective study at one center, so it shows a link and does not prove cause. Larger prospective studies are needed.
Researchers published the plan for DAPA-LN, a multicentre randomized trial testing whether the diabetes and kidney drug dapagliflozin improves kidney response in people with biopsy-confirmed lupus nephritis who already take stable immune-suppressing treatment and a blood-pressure drug that protects the kidneys. This is a trial protocol only. There are no results yet.
Researchers found that neutrophils (a type of white blood cell) from people with lupus, unlike those from healthy people or people with rheumatoid arthritis, contain many mis-spliced gene messages that make unusual protein pieces. Immune T cells from patients reacted to these pieces, and patients' blood also held antibodies against them. This is lab research in patient samples; it points to a possible cause and future treatment target, not a treatment.
In the first part of the AMETHYST study, 14.7% of people on litifilimab had clear or almost clear skin (erythema score 0-1) at week 16 versus 2.9% on placebo (P=.0263). At week 24, 21.7% vs 5.8% reached a 70% improvement in skin disease score (CLASI-70). The drug was generally well tolerated. The study was not built to prove the secondary results. Not yet an approved treatment.
Brazil's health regulator, Anvisa, approved Gazyva (obinutuzumab) for adults with moderate to severe active lupus who test positive for autoantibodies and are already on standard treatment. The U.S. FDA decision on Gazyva for lupus is still expected by December 2026.
At the EADV congress, Biogen reported that 27.2% of people given litifilimab from the start had clear or almost clear skin at week 52, up from 19.0% at week 24. People who switched from placebo at week 24 improved within four weeks. Biogen said no new safety signals appeared. Phase 3 results are expected in the first half of 2027. Company-reported; cutaneous lupus only.
Biogen's TOPAZ-1 and TOPAZ-2 (litifilimab) list primary completion in late September 2026, and BMS's POETYK SLE-1 and SLE-2 (deucravacitinib) in October 2026. No results have been posted yet.
Adicet's off-the-shelf gamma delta CAR-T cells, which target CD20, were given to 22 evaluable patients. At 12 months, 54% were in remission (DORIS) and 50% of those with lupus nephritis had a complete kidney response. All stopped immune drugs. No graft-versus-host disease. Infections occurred in 54%. A company release, not yet peer reviewed.
In 12 people with active SLE, there were no serious treatment-related side effects. At 12 months, 8 of 10 reached low disease activity and 6 of 10 reached remission. Small and uncontrolled.
In a 53-person randomized trial, 12 weeks of interval training raised aerobic fitness but did not reduce fatigue compared with no training.
In 9 adults with severe, treatment-resistant lupus, 5 of 6 at the lower dose reached remission, with several kidney responses. No severe nerve toxicity. One reversible liver injury. Investigators called it "early days."
In 321 people, 50% responded on the CD40 ligand blocker vs 35% on placebo at 48 weeks. Serious infections were 4% vs 6%. One death from sepsis was reported in the drug group. A second Phase 3 (PHOENYCS FLY) is recruiting.
In 102 people with active cutaneous or systemic lupus skin disease, this oral TLR7/8 blocker cut skin activity by 64–72% vs 44% on placebo at 16 weeks.
A once-weekly 120 mg autoinjector for adults with moderate to severe SLE on standard therapy, based on the TULIP-SC Phase 3 trial.
Based on ALLEGORY, the FDA accepted Genentech's application for obinutuzumab in SLE, with a decision expected by December 2026. The data were also submitted in Europe.
Of 18 patients (15 children), 12 of 15 with active disease responded at 6 months and 2 did not. Responders stayed off immune drugs over a median 10 months, with 1 relapse.
In 303 adults without active nephritis, 76.7% responded on obinutuzumab vs 53.5% on placebo at week 52, and it beat placebo on all key secondary goals. Serious side effects: 15.9% vs 11.9%.
Autolus's Phase 2 trial of obe-cel in severe lupus with active kidney disease began January 16, 2026 and is recruiting in the U.S., UK, Europe, Brazil and Vietnam.
In 1,768 people in the Hopkins Lupus Cohort, a starting vitamin D level under 20 ng/mL was linked to more deaths and heart events. The authors question whether supplements change that risk.
Hydroxychloroquine is the base of care. Four targeted drugs are FDA approved for lupus or lupus nephritis, and cell therapies are in trials.
One of the main lupus medicines. The Lupus Foundation of America notes it also helps protect against sun sensitivity. It needs regular eye checks.
Blocks a signal (BLyS) that keeps B cells alive. Given as an infusion or a shot under the skin, added to standard therapy.
Blocks the type I interferon receptor. For adults with moderate to severe SLE on standard therapy. The new under-the-skin pen lets people treat at home.
A twice-daily capsule that calms immune T cells, used with other immune drugs to treat lupus kidney disease.
Removes B cells. In the REGENCY trial, 46.4% had a complete kidney response vs 33.1% on standard therapy alone. A decision for non-kidney lupus is expected by December 2026.
Immune cells are engineered to destroy B cells. Small studies report remissions without other immune drugs, but it isn't approved, needs chemotherapy first in most versions, and long-term results are unknown.
| Treatment | For | What it does |
|---|---|---|
| Hydroxychloroquine | Most people with lupus | Calms the immune system and helps prevent flares. |
| Corticosteroids (e.g. prednisone) | Flares | Quickly reduce inflammation. Doctors try to lower the dose over time. |
| Belimumab or anifrolumab | Active SLE despite standard therapy | Targeted biologics added to standard care. |
| Mycophenolate plus voclosporin, belimumab or obinutuzumab | Lupus nephritis | Protects the kidneys and aims for a complete kidney response. |
| Sun protection | Everyone with lupus | Reduces UV-triggered rashes and flares. |
No diet or supplement cures lupus. The Lupus Foundation of America says there is no specific lupus diet. Some "immune-boosting" products may make it worse. We rate each by the strength of evidence.
UV light from the sun or some indoor lights can trigger flares. The Lupus Foundation of America advises broad-spectrum SPF 30+ sunscreen, reapplied every two hours, plus tightly woven clothing and a wide-brimmed hat.
Very low levels are linked to worse outcomes, and the Foundation suggests having levels checked. It isn't proven that supplements change lupus risk.
A 2026 randomized trial found interval training improved fitness, though not fatigue.
They contain L-canavanine, which may increase inflammation by stimulating the immune system. Johns Hopkins and the Lupus Foundation say to avoid them.
Sold as an immune booster, which may cause flares. The Lupus Foundation of America does not support its use in lupus.
Johns Hopkins lists garlic among things to avoid because it may stimulate an already overactive immune system.
Be careful: some medicines, including sulfa antibiotics (Bactrim, Septra), can raise sun sensitivity or lower blood counts in lupus. Tell every doctor you have lupus, and check any supplement with your care team before starting it.
Centers recognized for expertise in this condition, and communities of people living with it.
Specializes in lupus and antiphospholipid syndrome. Its Hopkins Lupus Cohort has followed patients enrolled since 1988 and included 2,931 people in a 2025 study.
Its team published CD19 CAR-T results in 5 lupus patients (Nature Medicine, 2022) and a 15-patient follow-up that included 8 people with lupus (NEJM, 2024).
France's national rare-disease reference center for lupus and antiphospholipid syndrome, part of the European Reference Network ReCONNECT.
A listed site in Autolus's CARLYSLE Phase 1 trial of obe-cel CAR-T cells for severe, treatment-resistant lupus.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Lupus can be unpredictable and hard to explain to others. These groups connect people who understand. Most are free.
National specialty groups (for example for men, young people, or kidney disease), statewide groups, the LupusConnect online community and a health-educator service.
Visit ↗A free helpline, regional support groups and an online peer-support forum on HealthUnlocked.
Visit ↗Funds lupus research and shares research news, webinars and ways to join studies through its affiliate Lupus Therapeutics.
Visit ↗Many private patient and caregiver groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Hydroxychloroquine and steroids are used everywhere. Newer biologics reached the U.S., Europe and Japan first. Much of the cell-therapy research is happening in Germany, the UK and China.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Belimumab (Benlysta)SLE, lupus nephritis | Approved 2011 | Approved 2011 | NICE 2021 | — | Approved 2017 | — | Approved 2019 | — | — |
| Anifrolumab (Saphnelo)SLE | Approved 2021 | Approved 2022 | — | — | Approved 2021 | — | — | — | — |
| Voclosporin (Lupkynis)Lupus nephritis | Approved 2021 | Approved 2022 | NICE 2023 | — | — | — | — | — | — |
| Obinutuzumab (Gazyva)Lupus nephritis | Approved 2025 | Approved 2025 | — | — | — | — | — | — | — |
| HydroxychloroquineStandard care | Used | — | — | — | — | — | — | — | — |
The Phase 1 CARLYSLE trial runs at UK and Spanish hospitals. The Phase 2 LUMINA trial in lupus nephritis began in January 2026.
Researchers in Wuhan and at Stanford reported a ready-made antibody that depletes B cells without making custom cells for each patient.
A Beijing-led trial treated 18 patients, 15 of them children, the largest pediatric group we found in a published lupus CAR-T trial.
Lupus is an autoimmune disease: the immune system attacks healthy cells. The exact cause isn't known. It seems to take a mix of genes, hormones and triggers in the environment.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help people with lupus and their families pay for care and costs. Funds are limited and rules vary, so contact each one directly.
Run by its PA Fund for Patient Advocacy. One-time grants of up to $500 for urgent costs such as overdue rent with an eviction notice, utility shut-offs or emergency medical treatment. Six grants are given each month, one per person per 12 months, and only while funds last.
See the program ↗Helps with costs tied to lupus treatment or a lupus emergency, paid directly to the provider. Up to 2 grants and $500 a person in any 12 months; it does not pay rent, mortgage or car payments. Call or email for an application.
See the grants ↗Formerly Molly's Fund. Its Emergency Client Assistance Program, run with St. Vincent de Paul, gives emergency help with housing or rent, utilities, transportation and prescriptions.
See the program ↗Up to $500 per request, paid to vendors, for medical equipment, rides to appointments, short-term critical needs, wellness support, and respite or short-term home care. It doesn't pay past expenses, credit cards or insurance premiums. Requests are reviewed monthly.
See the fund ↗Helps pay prescription copays or Medicare Part B premiums. The fund was listed as closed on October 6, 2026, but funds reopen from time to time.
Check fund status ↗Has lupus (SLE) funds that help with treatment costs. Both were listed as closed on October 6, 2026; you can sign up to hear when they reopen.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: hydroxychloroquine's need for eye checks, the role of corticosteroids and dose tapering, how each drug works (BLyS, interferon receptor, T-cell calcineurin, CD20), and that most CAR-T versions need chemotherapy first, which reflect the established medical literature and the drugs' labels. Hydroxychloroquine's 1955 FDA date is the original Plaquenil approval in Drugs@FDA, not a lupus-specific approval date. Where a news source and Drugs@FDA differ on an approval date (Gazyva for lupus nephritis: Oct 20 vs Oct 17, 2025; Saphnelo autoinjector: Apr 27 vs Apr 24, 2026), the Drugs@FDA date is used. The prula-cel results come only from the company's release and have not been peer reviewed. The CARLYSLE EULAR 2026 numbers come from a university news report, not a published paper. The "NICE" cells mean NICE recommended the drug for NHS use in England, not a separate approval date. The "Used" entry for hydroxychloroquine and all "—" cells in the approvals table are unverified. A Reddit lupus community is not listed because we could not open Reddit to confirm it. Expert care centers: No international center-of-excellence designation for lupus could be verified. Pitié-Salpêtrière holds an official French national reference-center designation. The others are listed for published research or a registered trial role, and only four could be verified. Financial help: checked October 6, 2026. Kaleidoscope, Lupus Foundation of America, HealthWell and TotalAssist pages block automated checks and were read with a headless browser. Lupus LA's page shows no open or closed status. Left out: the Lupus Foundation of America Heartland fund (no amounts or current status shown), the PAN Foundation lupus fund (page could not be opened) and The Assistance Fund (waitlist only, no details on its page).